Search by Drug Name or NDC
NDC 72611-0785-02 Temsirolimus Details
Temsirolimus
Temsirolimus is a KIT in the HUMAN PRESCRIPTION DRUG category. It is labeled and distributed by Almaject, Inc.. The primary component is .
MedlinePlus Drug Summary
Temsirolimus is used to treat advanced renal cell carcinoma (RCC, a type of cancer that begins in the kidney). Temsirolimus is in a class of medications called kinase inhibitors. It works by blocking the action of the abnormal protein that tells the cancer cells to multiply. This may help slow the growth of tumors.
Related Packages: 72611-0785-02Last Updated: 12/01/2022
MedLinePlus Full Drug Details: Temsirolimus
Product Information
| NDC | 72611-0785 |
|---|---|
| Product ID | 72611-785_43d87a8b-7237-64cd-165f-09894680db15 |
| Associated GPIs | 21532570002020 |
| GCN Sequence Number | 062826 |
| GCN Sequence Number Description | temsirolimus VIAL FDN 30MG/3 INTRAVEN |
| HIC3 | V3C |
| HIC3 Description | ANTINEOPLASTIC - MTOR KINASE INHIBITORS |
| GCN | 98597 |
| HICL Sequence Number | 034870 |
| HICL Sequence Number Description | TEMSIROLIMUS |
| Brand/Generic | Generic |
| Proprietary Name | Temsirolimus |
| Proprietary Name Suffix | n/a |
| Non-Proprietary Name | Temsirolimus Injection |
| Product Type | HUMAN PRESCRIPTION DRUG |
| Dosage Form | KIT |
| Route | n/a |
| Active Ingredient Strength | n/a |
| Active Ingredient Units | n/a |
| Substance Name | n/a |
| Labeler Name | Almaject, Inc. |
| Pharmaceutical Class | n/a |
| DEA Schedule | n/a |
| Marketing Category | ANDA |
| Application Number | ANDA207383 |
| Listing Certified Through | 2024-12-31 |
Package
NDC 72611-0785-02 (72611078502)
| NDC Package Code | 72611-785-02 |
|---|---|
| Billing NDC | 72611078502 |
| Package | 1 KIT in 1 CARTON (72611-785-02) * 1 mL in 1 VIAL, SINGLE-DOSE (72611-780-01) * 1.8 mL in 1 VIAL, SINGLE-DOSE (72611-782-01) |
| Marketing Start Date | 2020-05-08 |
| NDC Exclude Flag | N |
| Pricing Information | N/A |